ECOG E2408- Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

Objective

This randomized phase II trial is studying giving bendamustine hydrochloride and rituximab together with or without bortezomib followed by rituximab with or without lenalidomide to see how well they work in treating patients with high-risk stage II, stage III, or stage IV follicular lymphoma. 

http://clinicaltrials.gov/ct2/show/NCT01216683

Location:

Essentia Health Brainerd, Essentia Health Duluth, Essentia Health Fargo

Disclosures:

None

For more information about a financial conflict of interest (FCOI), review the Essentia Health FCOI policy.

Last Updated: 07/09/2012

Research Study Categories

  • Adult Studies

Specialty

  • Cancer
  • Hematology
Contact
Cancer Clinical Trials at 218-786-3308

Like most websites, we use cookies and other technologies to keep our website reliable, secure, and to better understand how our site is used. By using our site, you agree to our use of these tools. Learn more.